# QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

> **NCT06852456** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)Injection
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06852456
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2030-12
- **Final completion:** 2034-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06852456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06852456, "QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06852456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*